文献速递MDS 与骨髓增殖性肿瘤

苏木精结合突变型钙网蛋白并破坏其与血小板生成素受体的异常相互作用

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
PubMed 文献 · Blood · 2021-01-01

本研究针对CALR突变驱动的骨髓增殖性肿瘤,通过计算机分子对接筛选靶向CALR的N-糖基结合域(GBD)的小分子,发现一组儿茶酚类化合物对依赖致癌性CALR生存的细胞具有选择性生长抑制作用,并实验证实其直接结合CALR、破坏突变型CALR-MPL相互作用、抑制JAK2-STAT5通路并降低突变型CALR胞内水平。

要点

  • 靶向CALR的GBD小分子可选择性抑制CALR突变细胞生长并诱导凋亡。
  • 苏木精类化合物直接结合CALR,破坏突变型CALR-MPL相互作用。
  • 药物作用伴随JAK2-STAT5通路抑制及突变型CALR胞内水平降低。

核心结论

  • 靶向CALR的GBD的小分子可通过破坏突变型CALR-MPL相互作用和抑制致癌信号选择性杀伤CALR突变细胞。

研究设计与样本

  • 研究采用计算机分子对接筛选靶向CALR的GBD的候选结合物,并通过实验验证命中化合物。

主要发现

  • 一组儿茶酚类化合物对依赖致癌性CALR生存和增殖的细胞具有选择性生长抑制作用。
  • 化合物诱导的凋亡在CALR突变细胞中显著高于CALR野生型细胞。
  • CALR敲除或C端截断消除了CALR突变细胞对药物的超敏反应。
  • 实验证实所选化合物直接结合CALR,破坏突变型CALR-MPL相互作用,抑制JAK2-STAT5通路,并降低突变型CALR的胞内水平。

临床怎么用

  • 提示靶向CALR的GBD的小分子可能成为CALR突变骨髓增殖性肿瘤的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutations of calreticulin (CALR) have been identified as a main disease driver of myeloproliferative neoplasms, suggesting that development of drugs targeting mutant CALR is of great significance. Site-directed mutagenesis in the N-glycan binding domain (GBD) abolishes the ability of mutant CALR to oncogenically activate the thrombopoietin receptor (MPL). We therefore hypothesized that a small molecule targeting the GBD might inhibit the oncogenicity of the mutant CALR. Using an in silico molecular docking study, we identified candidate binders to the GBD of CALR. Further experimental validation of the hits identified a group of catechols inducing a selective growth inhibitory effect on cells that depend on oncogenic CALR for survival and proliferation. Apoptosis-inducing effects by the compound were significantly higher in the CALR-mutated cells than in CALR wild-type cells. Additionally, knockout or C-terminal truncation of CALR eliminated drug hypersensitivity in CALR-mutated cells. We experimentally confirmed the direct binding of the selected compound to CALR, disruption of the mutant CALR-MPL interaction, inhibition of the JAK2-STAT5 pathway, and reduction at the intracellular level of mutant CALR upon drug treatment. Our data indicate that small molecules targeting the GBD of CALR can selectively kill CALR-mutated cells by disrupting the CALR-MPL interaction and inhibiting oncogenic signaling.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jia R, Balligand T, Atamanyuk V, et al. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor. Blood. 2021. PMID: 33202418. doi:10.1182/blood.2020006264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。